{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of Confidence Interval has not been achieved due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"5.6","upperLimit":"NA","value":"5.6"},{"comment":"Upper limit of Confidence Interval has not been achieved due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"8.7","upperLimit":"NA","value":"26.2"},{"groupId":"OG002","lowerLimit":"6.2","upperLimit":"13.3","value":"10.3"},{"groupId":"OG003","lowerLimit":"10.5","upperLimit":"21.7","value":"16.6"},{"groupId":"OG004","lowerLimit":"10.0","upperLimit":"19.6","value":"16.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"44"}],"units":"Participants"}],"description":"Time from the date of first study treatment administration Phase Ib, Phase II part 1 or time from the date of randomization Phase II part 2 Cohort A to the date of death due to any cause.\n\nIf a patient is not known to have died survival will be censored at the date of last contact.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received 5x10e6 pfu ofTG4001 subcutaneously along with 10 mg/kg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"OG000","title":"Phase I - TG4001 5x10e6 Pfu"},{"description":"Participants received 5x10e7 pfu TG4001 subcutaneously along with 10 mg/kg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"OG001","title":"Phase I - TG4001 5x10e7 Pfu + Avelumab"},{"description":"Participants received 5x10e7 pfu TG4001 subcutaneously along with 10 mg/kg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"OG002","title":"Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab"},{"description":"Participants received 5x10e7 pfu TG4001 subcutaneously along with 800 mg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"OG003","title":"Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab"},{"description":"Participants received 800 mg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"OG004","title":"Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab"}],"paramType":"MEDIAN","populationDescription":"Phase Ib: All participants included and who received any amount of study treatment.\n\nPhase II part 1: Evaluable participants' population. Phase II part 2 Cohort A: All randomized participants who were administered at least one dose of IMP(s) according to the treatment allocated at randomization.\n\nFor the Phase II part 2 Cohort B, the outcome measure Overall Survival has not been defined as secondary endpoint. Therefore Phase II part 2 Cohort B is not included in the analysis population.","reportingStatus":"POSTED","timeFrame":"From treatment start : Phase Ib, Phase II part 1 / from randomization: Phase II part 2 Cohort A through study completion, for an average of 4.5 years.","title":"Overall Survival (OS) : Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A","type":"SECONDARY","unitOfMeasure":"Months"}